GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Cost of Goods Sold

SI-BONE (SI-BONE) Cost of Goods Sold : $29.5 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Cost of Goods Sold?

SI-BONE's cost of goods sold for the three months ended in Dec. 2023 was $10.2 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $29.5 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SI-BONE's Gross Margin % for the three months ended in Dec. 2023 was 73.8%.

Cost of Goods Sold is also directly linked to Inventory Turnover. SI-BONE's Inventory Turnover for the three months ended in Dec. 2023 was 0.48.


SI-BONE Cost of Goods Sold Historical Data

The historical data trend for SI-BONE's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE Cost of Goods Sold Chart

SI-BONE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial 6.79 8.90 10.43 15.71 29.47

SI-BONE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.09 5.92 6.32 7.04 10.18

SI-BONE Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SI-BONE  (NAS:SIBN) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SI-BONE's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(38.859 - 10.183) / 38.859
=73.8 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

SI-BONE's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


SI-BONE Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of SI-BONE's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


SI-BONE (SI-BONE) Business Description

Traded in Other Exchanges
N/A
Address
471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Executives
Anshul Maheshwari officer: Chief Financial Officer 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero officer: Chief Commercial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn director, officer: Chairman, President & CEO C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis officer: Chief Financial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky officer: GC & Chief Compliance Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh director 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp 10 percent owner 525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling officer: CMO and VP, Medical Affairs C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby officer: Chief Technology Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451